SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION
13 OR 15 (D)
of
the
SECURITIES EXCHANGE
ACT OF 1934
Date of
Report (Date of earliest event reported): August,
2016
Sample
Global Corporation
(Exact
name of registrant as specified in its charter)
NEVADA
(State
or other jurisdiction of incorporation or
organization)
|
33-115906
|
76-0678366
|
|
(Commission File
Number)
|
(IRS
Employer Identification Number)
|
476
Thompson Place
Sunnyvale,
CA 94086
(Address of
principal executive offices)
Paul T.
Schena
476
Thompson Place
Sunnyvale,
CA 94086
(Name
and address of agent for service)
408-577-3468
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☒
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☒
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☒
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☒
|
Pre-commencement
communications pursuant to Rule 13e-4 (c) under the Exchange Act
(17 CFR 240.13e-4(c))
|
ITEM
8.01 – Other Events
SUNNYVALE,
California – September 21, 2015 – Sample Corporation
filed a Certificate of Amendment to Articles of Incorporation for
Nevada Profit Corporations (Pursuant to NRS 78.385 and 78.390
– After Issuance of Stock) to increase authorized shares.
Article V Capital Stock has been amended to read as
follows:
|
SAMPLE & RESOURCE
COMPANY, LLC
|
||||
|
|
|
|
||
|
|
Three Months Ended
September 30,
|
Nine
Months Ended September 30,
|
||
|
|
2005
|
2004
|
2005
|
2004
|
|
Revenues:
|
|
|
|
|
|
Sale of
Land
|
$3,888,000
|
$1,082,000
|
$7,666,000
|
$3,452,000
|
|
Lease and
Royalty
|
145,000
|
159,000
|
431,000
|
475,000
|
|
Interest and
Other
|
554,000
|
95,000
|
698,000
|
284,000
|
|
Segment Total
Revenues
|
$4,277,000
|
$1,336,000
|
$8,795,000
|
$4,211,000
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
Cost of Land
Sales
|
$(1,436,000)
|
$(483,000)
|
$(2,572,000)
|
$(1,765,000)
|
|
Operating
Expenses
|
(462,000)
|
(392,000)
|
(1,427,000)
|
(1,338,000)
|
|
Segment Total
Expenses
|
$(1,898,000)
|
$(875,000)
|
$(3,999,000)
|
$(3,103,000)
|
|
|
|
|
|
|
|
Income Before
Tax
|
$2,379,000
|
$461,000
|
$4,796,000
|
$1,108,000
|
Nevada
Land recognizes revenue from land sales, and the resulting gross
profit or loss, when the sales transactions close.
On
closing, the entire sales price is recorded as revenue, and a gross
margin is recognized depending on the cost basis attributed to the
land which was sold. Since the date of closing determines the
accounting period in which the sales revenue and gross margin are
recorded:
On
closing, the entire sales price is recorded as revenue, and a gross
margin is recognized depending on the cost basis attributed to the
land which was sold. Since the date of closing determines the
accounting period in which the sales revenue and gross margin are
recorded:
●
Nevada Land’s
reported revenues and income fluctuate from quarter to quarter
depending on the dates when specific transactions close;
and
●
John was
here
●
Land sales revenues
for any individual quarter are not indicative of likely full-year
revenues.
o
Nevada Land’s
reported revenues and income fluctuate from quarter to quarter
depending on the dates when specific transactions close;
and
o
John was here
twice
o
Land sales revenues
for any individual quarter are not indicative of likely full-year
revenues.
In the
third quarter of 2005, segment total revenues were $4.3 million.
Nevada Land sold approximately 50,677 acres of land for $3.9
million. The average sales price was $77 per acre, and our average
basis in the land sold was $28 per acre. The gross margin on land
sales was $2.5 million, which represents a gross margin percentage
of 63.1%.
Number
and Designation. The total number of shares of all classes that
this Corporation shall have authority to issue shall be
980,000,000, of which 960,000,000 shall be shares of common stock,
par value $.0.001 per share (“Common Stock”) , and
20,000,000 shall be shares of preferred stock, par value $.0.001
per share (“Preferred Stock”).
Stockholders
entitled to exercise voting power of 561,100,050 shares in the
corporation (57%) voted in favor of this amendment.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
Sample
Corporation
|
|
|
|
|
|
|
|
|
Date:
September 21, 2015
|
By:
|
/s/
Rene A. Schena
|
|
|
|
|
Name:
Paul T. Schena
|
|
|
|
|
Title:
Chief Executive Officer
|
|
ESSA
Pharma Announces Closing of US$5 Million Private
Placement
HOUSTON, TX and
VANCOUVER, March 21, 2016 /CNW/ - ESSA Pharma Inc. ("ESSA" or the
"Company") (TSX: EPI, NASDAQ: EPIX) is pleased to announce that it
has closed a non-brokered private placement (the "Private
Placement") of 1,666,666 common shares in the capital of the
Company ("Common Shares") at US$3.00 per Common Share to Eventide
Funds for gross proceeds of approximately US$5 million. The Company
intends to use the net proceeds from the Private Placement for
general corporate purposes, including funding research and
development, preclinical and clinical expenses, and corporate
costs. David Parkinson, MD, ESSA's President and CEO
commented,
●
"The proceeds of
this strategic financing combined with our recently completed
financing in January are anticipated to provide the company with a
healthy financial position going into the clinical trial program."
All securities issued pursuant to the Private Placement are subject
to a four month and one day hold period in Canada in accordance
with applicable securities laws.
Within
30 days of closing, the Company expects to file a prospectus
supplement under its Registration Statement on Form F-10 with
respect to resales in the United States, from time to time, of the
Common Shares purchased by Eventide Funds. Upon filing of the
prospectus supplement, such Common Shares will be freely tradeable
in the United States.
The
Common Shares have not been registered under the United States
Securities Act of 1933, as amended, and may not be offered or sold
in the United States absent registration or an applicable exemption
from registration requirements.
Forward-Looking
Statement Disclaimer
Certain
statements in this news release contain forward-looking information
within the meaning of the Private Securities Litigation Reform Act
of 1995 and/or Canadian securities laws that may not be based on
historical fact, including without limitation, statements
containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar
expressions. Forward-looking statements in this news release
include, but are not limited to, statements regarding the
anticipated use of the proceeds of the Private Placement, the
funding of ESSA's Phase1/2 program and the filing of a prospectus
supplement by ESSA and the ability to trade the Common Shares in
the United States thereafter.
Forward-looking
statements and information are subject to various known and unknown
risks and uncertainties, many of which are beyond the ability of
ESSA to control or predict, and which may cause ESSA's actual
results, performance or achievements to be materially different
from those expressed or implied thereby. Such statements reflect
ESSA's current views with respect to future events, are subject to
risks and uncertainties and are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by ESSA
as of the date of such statements, are inherently subject to
significant medical, scientific, business, economic, competitive,
political and social uncertainties and contingencies. In making
forward-looking statements, ESSA may make various material
assumptions, including but not limited to the market and demand for
the securities of ESSA, general business, market and economic
conditions, obtaining positive results of clinical trials,
obtaining regulatory approvals and the ability of ESSA to file a
resale prospectus supplement in the United States.
Forward-looking
information is developed based on assumptions about such risks,
uncertainties and other factors including, among others, the
general economic and business conditions in the United States,
Canada, Europe and the other regions in which ESSA operates, not
receiving required regulatory approvals, ESSA's projected cash
position, revenues and expenses being accurate, the inability of
ESSA to file a resale prospectus supplement in the United States
and the additional factors discussed in or referred to under the
heading "Risk Factors" in ESSA's Annual Report on Form 20-F for the
year ended September 30, 2015 which is available under ESSA's
profile on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
Forward-looking statements are made based on management's beliefs,
estimates and opinions on the date that statements are made and
ESSA undertakes no obligation to update forward-looking statements
if these beliefs, estimates and opinions or other circumstances
should change, except as may be required by applicable law. Readers
are cautioned against attributing undue certainty to
forward-looking statements.
SOURCE
ESSA Pharma Inc
For
further information: David Wood, Chief Financial Officer, ESSA
Pharma Inc., T: (778) 331-0962, E:
dwood@essapharma.com
CO:
ESSA Pharma Inc
CNW
19:52e 21-MAR-16